Semma Therapeutics Inc., of Cambridge, Mass., a company focused on the development of regenerative medicines, has completed an oversubscribed $114 million series B financing. Proceeds will be used to bring its lead development program, encapsulated stem cell-derived islets, through clinical proof of concept in patients and to continue exploration of other regenerative medicine therapeutics, the company said.